Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL

• Published in: Blood advances 2017-09, Vol.1 (20), p.1657-1671
• Main Authors: Roberts, Kathryn G., Yang, Yung-Li, Payne-Turner, Debbie, Lin, Wenwei, Files, Jacob K., Dickerson, Kirsten, Gu, Zhaohui, Taunton, Jack, Janke, Laura J., Chen, Taosheng, Loh, Mignon L., Hunger, Stephen P., Mullighan, Charles G.
• Format: Article
• Language: English
• Subjects: Lymphoid Neoplasia
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2017011296

New therapies for Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) patients are urgently needed. The genetic landscape of Ph-like ALL is characterized by a diverse array of kinase-activating alterations (including rearrangements, sequence mutations, and copy number alterations), suggesting that patients with Ph-like ALL are candidates for targeted therapy, similar to BCR-ABL1 ALL. We sought to investigate the functional role and targetability of the spectrum of kinase-activating alterations identified in Ph-like ALL. We demonstrate cytokine-independent growth and activation of JAK-STAT signaling pathways in Ba/F3 cells by all alterations tested. The development of murine Arf−/− pre-B ALL expressing RCSD1-ABL2 or SSBP2-CSF1R was accelerated with the presence of IK6, a dominant negative isoform of Ikaros common in Ph-like ALL, providing evidence that these fusions are leukemogenic. In vitro screening using a panel of tyrosine kinase inhibitors against 14 different kinase alterations identified the ABL1-inhibitor, dasatinib, as a potent inhibitor of ABL-class fusions (ABL1, ABL2, CSF1R, PDGFRB), whereas the JAK1/JAK2 inhibitor ruxolitinib, was most effective against JAK-STAT–activating alterations (JAK1, JAK2, JAK3, IL7R, IL2RB), but not TYK2. Evaluation of dasatinib or ruxolitinib against patient-derived xenograft models demonstrated superior antileukemic efficacy when combined with dexamethasone compared with either agent alone. These data provide the foundation for rationally designed clinical trials that assess the efficacy of targeted therapy in patients with Ph-like ALL. [Display omitted] •The majority of kinase alterations identified in Ph-like ALL can be targeted with either ABL or JAK inhibition.•Enhanced efficacy of tyrosine kinase inhibitor therapy was observed with dexamethasone in patient-derived xenograft models of Ph-like ALL.